Complex renal cysts associated with crizotinib treatment

Cancer Medicine

Volumn 4, Issue 6, 2015, Pages 887-896

  Schnell, Patrick ^a   Bartlett, Cynthia H ^a   Solomon, Benjamin J ^b   Tassell, Vanessa ^a   Shaw, Alice T ^c   de Pas, Tommaso ^d   Lee, Soo Hyun ^e   Lee, Geon Kook ^e   Tanaka, Kaoru ^f   Tan, Weiwei ^a   Tang, Yiyun ^a   Wilner, Keith D ^a   Safferman, Allan ^a   Han, Ji Youn ^e  

^a PFIZER INC   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e National Cancer Center   (South Korea)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

NSCLC; Crizotinib; Independent radiologic review; Renal cysts; Risk factors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CYST; KOREAN (PEOPLE); LABORATORY TEST; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; KIDNEY POLYCYSTIC DISEASE; LUNG NEOPLASMS; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KIDNEY DISEASES, CYSTIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85006226114     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.437     Document Type: Article

References (29)

1. Christensen, J. G., H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, et al. 2007. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6:3314-3322.
2. Zou, H. Y., Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, et al. 2007. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67:4408-4417.
3. Rikova, K., A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, et al. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203.
4. Soda, M., Y. L. Choi, M. Enomoto, S. Takeda, Y. Yamashita, S. Ishikawa, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
5. Weickhardt, A. J., and D. R. Camidge . 2011. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin. Invest. 1:1119-1126.
6. Blackhall, F., S. Peters, K. M. Kerr, K. O'Byrne, H. Hager, A. Sejda, et al. 2012. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: preliminary results from the European thoracic oncology platform Lungscape project. Ann. Oncol. 23(Suppl. 9):ix73(Abstract 1670).
7. Shaw, A. T., D. W. Kim, K. Nakagawa, T. Seto, L. Crino, M. J. Ahn, et al. 2013. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368:2385-2394.
8. Weber, T. M.. 2006. Sonography of benign renal cystic disease. Ultrasound Clin. 1:15-24.
9. Davidson, A. J., D. S. Hartman, P. L. Choyke, and B. J. Wagner . 1997. Radiologic assessment of renal masses: implications for patient care. Radiology 202:297-305.
10. Carrim, Z. I., and J. T. Murchison . 2003. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin. Radiol. 58:626-629.
11. Eknoyan, G. 2009. A clinical view of simple and complex renal cysts. J. Am. Soc. Nephrol. 20:1874-1876.
12. Minor, L. D., M. M. Picken, and S. C. Campbell . 2003. Pp. 170-171 in AUA update series (Vol. 22): benign renal tumors. American Urological Association, Houston, TX.
13. Mosharafa, A. A. 2008. Prevalence of renal cysts in a Middle-Eastern population: an evaluation of characteristics and risk factors. BJU Int. 101:736-738.
14. Dong, S., N. Patel, C. Kundavaram, D. Glassman, and D. Bagley . 2011. A contemporary study of renal cysts in a representative US population. Presented at the New England and Mid-Atlantic Sections of the American Urological Association 2011 Joint Annual Meeting, Orlando, FL, 3-5 November 2011. Available at http://meeting.neaua.org/abstracts/2011/6.cgi (accessed 4 November 2014).
15. Prasad, S. R., N. C. Dalrymple, and V. R. Surabhi . 2008. Cross-sectional imaging evaluation of renal masses. Radiol. Clin. North Am. 46:95-111.
16. Israel, G. M., and M. A. Bosniak . 2005. An update of the Bosniak renal cyst classification system. Urology 66:484-488.
17. Kwak, E. L., Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363:1693-1703.
18. Camidge, D. R., Y. J. Bang, E. L. Kwak, A. J. Iafrate, M. Varella-Garcia, S. B. Fox, et al. 2012. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13:1011-1019.
19. Kim, D.-W., M.-J. Ahn, Y. Shi, T. M. De Pas, P.-C. Yang, G. J. Riely, et al. 2012. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl.): (Abstract 7533).
20. Solomon, B. J., T. Mok, D. W. Kim, Y. L. Wu, K. Nakagawa, T. Mekhail, et al. 2014. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371:2167-2177.
21. Klempner, S. J., G. Aubin, A. Dash, and S. H. Ou . 2014. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 19:1008-1010.
22. Lin, Y. T., Y. F. Wang, J. C. H. Yang, C. J. Yu, S. G. Wu, J. Y. Shih, et al. 2014. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J. Thorac. Oncol. 9:1720-1725.
23. Varella-Garcia, M., L. D. Berry, P.-F. Su, W. A. Franklin, A. J. Iafrate, M. Ladanyi, et al. 2012. ALK and MET genes in advanced lung adenocarcinomas: the lung cancer mutation consortium experience. J. Clin. Oncol. 30(Suppl.): (Abstract 7589).
24. Li, C., C. Alvey, A. Bello, K. D. Wilner, and W. Tan . 2011. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J. Clin. Oncol. 29(Suppl.): (Abstract e13065).
25. Sierra, J. R., and M. S. Tsao . 2011. c-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. 3(Suppl. 1):S21-S35.
26. Horie, S., E. Higashihara, K. Nutahara, Y. Mikami, A. Okubo, M. Kano, et al. 1994. Mediation of renal cyst formation by hepatocyte growth factor. Lancet 344:789-791.
27. Konda, R., H. Sato, F. Hatafuku, T. Nozawa, N. Ioritani, and T. Fujioka . 2004. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J. Urol. 171:2166-2170.
28. Pécuchet, N., L. S. Fournier, and S. Oudard . 2013. New insights into the management of renal cell cancer. Oncology 84:22-31.
29. Whelan, T. F. 2010. Guidelines on the management of renal cyst disease. Can. Urol. Assoc. J. 4:98-99.